Bioverativ adds new member to board of directors
Biogen spinout, Bioverativ, have moved to consolidate its board of directors by appointing Anna Protopapas to the board. Protopapas becomes the fifth member of the Bioverativ board and brings with her extensive experience within the pharmaceutical industry.
Protopapas worked at Millennium Pharmaceutical for eight years before moving to Takeda Pharmaceutical to perform the role of Executive Vice President and Corporate Officers, Global Licensing and Business Development. She was then responsible for the integration of Millennium into Takeda. She is and will remain President and CEO of Mersana Therapeutics alongside her position on the board at Bioverativ.
“I am delighted to join Bioverativ’s board to help guide the continued success of the company’s haemophilia franchise and advancement of its novel pipeline programs,” said Ms. Protopapas on her appointment. “With its heritage of innovation, recent launch as an independent company, and singular focus on rare blood disorders, I believe that Bioverativ is poised to make great progress for patients.”
“Anna brings a proven track record of leading and growing biopharmaceutical companies, which will be extremely valuable as we work to deliver on our vision of building Bioverativ into a great rare disease company focused on blood disorders,” said John Cox, Chief Executive Officer at Bioverativ. “We are excited to have Anna join Bioverativ’s board.”